Clinical Trials Logo

Clinical Trial Summary

This study will examine the effects of regular almond consumption by individuals with elevated HbA1c on long-term glycemic control.


Clinical Trial Description

Globally, it is projected that 418 million people will have impaired glucose tolerance by 2025. In the US, an estimated 34 million Americans have diabetes and 88 million, 33% of adults, have pre-diabetes. Impaired glucose tolerance is now manifesting in young adults where 20% of those 12-18 years of age have prediabetes. The current prevalence of Type 2 diabetes is over 8%, but it is projected that up to a third of Americans will develop diabetes in their lifetime. Additionally, the total annual cost of diabetes is approximately $327 which accounts for 25% of all US health care costs. Moreover, the costs rose 60% from 2007 to 2017 and this trend is continuing. Diet is the preferred approach for management for this diet-related chronic disorder. Accumulating evidence suggests almond consumption decreases postprandial glycemia and may evoke a second meal effect, especially when they are consumed at breakfast or as an afternoon snack, which may aid in long-term glycemic control. Additionally, almond consumption can decrease total and LDL cholesterol, resulting in lower peripheral insulin resistance and cardiometabolic complications from type 2 diabetes mellitus. However, there is mixed evidence on the effects of almond consumption on HbA1c, a clinically important endpoint that provides a reliable measure of long-term glycemia and is correlated with risk of complications from diabetes. Thus, the investigators hypothesize a beneficial effect of regular almond consumption on long-term glycemic control in individuals with elevated baseline HbA1c. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05176197
Study type Interventional
Source Purdue University
Contact
Status Active, not recruiting
Phase N/A
Start date February 9, 2022
Completion date May 30, 2024

See also
  Status Clinical Trial Phase
Recruiting NCT05544266 - Rare and Atypical Diabetes Network
Completed NCT03241121 - Study of Eating Patterns With a Smartphone App and the Effects of Time Restricted Feeding in the Metabolic Syndrome N/A
Completed NCT03809182 - Effect of Dexmedetomidine on Postoperative Glucose and Insulin Levels. Phase 4
Completed NCT03675360 - Low-Carbohydrate Dietary Pattern on Glycemic Outcomes Trial N/A
Not yet recruiting NCT01402362 - Prevalence of Glucose Intolerance and Risk Factors in Ethiopian Immigrants in Israel; Follow-up Study. N/A
Completed NCT01671293 - Multicomponent Telecare Model for Supporting Prediabetes Patients N/A
Completed NCT00740363 - Sitagliptin in Renal Transplant Recipients Phase 4
Completed NCT00436475 - Vitamin D and Calcium Homeostasis for Prevention of Type 2 Diabetes Phase 1/Phase 2
Completed NCT04090788 - The Effect of Momordica Charantia Supplementation on Blood Glucose Levels N/A
Active, not recruiting NCT05460884 - Effects of Seaweed Extract on Postprandial Response to White Bread N/A
Not yet recruiting NCT05462834 - Impact of Nocturnal Hypoxemia on Glucose in High Altitude Sleep Disordered Breathing N/A
Completed NCT03348020 - Iron and Insulin Resistance in Overweight and Obese Humans N/A
Terminated NCT03356873 - Impact of Correction of Vitamin D Deficiency in Oxidative Stress in Patients With Prediabetes (VICOX) N/A
Completed NCT03922685 - Effects of Diet and Exercise on Circadian Glycemia N/A
Completed NCT03730727 - Exercise-meal Timing and Postprandial Glucose Control N/A
Completed NCT04743960 - Assessing Metabolic and Sleep Consequences of Overnight Home Parenteral Nutrition N/A
Completed NCT04004273 - Diabetes, Exercise and Liver Fat (DELIVER) N/A
Terminated NCT01887691 - Sleep Effectiveness and Insulin and Glucose Homeostasis Phase 1
Completed NCT02412995 - The Effects of Sea Buckthorn and Strawberry on Postprandial Glycaemia, Insulinemia and Appetite Phase 0
Not yet recruiting NCT01436448 - Probiotics (Lactobacillus Rhamnosus) in Reducing Glucose Intolerance During and After Pregnancy Phase 3